Experts explore new frontiers for AI in cancer care healthcareitnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthcareitnews.com Daily Mail and Mail on Sunday newspapers.
A study by researchers at Mayo Clinic Cancer Center has found that cancer patients diagnosed with COVID-19 who received care at home via remote patient monitoring were significantly less likely to require hospitalization for their illness, compared to cancer patients with COVID-19 who did not participate in the program.
Date Time
Remote patient monitoring may reduce need to hospitalize cancer patients
A study by researchers at Mayo Clinic Cancer Center has found that cancer patients diagnosed with COVID-19 who received care at home via remote patient monitoring were significantly less likely to require hospitalization for their illness, compared to cancer patients with COVID-19 who did not participate in the program. Results of the study were presented Friday, June 4, at the American Society of Clinical Oncology Annual Meeting and published in the Journal of Clinical Oncology.
“For our study, we evaluated 224 Mayo Clinic patients with cancer who were found to have COVID-19 through standardized screening prior to receiving cancer treatment, or due to symptoms or close exposure,” says Tufia Haddad, M.D., a Mayo Clinic medical oncologist and the study’s senior author. Researchers followed the patients March 18-July 31, 2020.
NXgenPort Announces Collaboration with Mayo Clinic
News provided by
Share this article
Share this article
MINNEAPOLIS and VENTURA, Calif., May 25, 2021 /PRNewswire/ NXgenPort, a biomedical technology company developing products to provide doctors with remote patient monitoring, announced today that it has entered into a license agreement with Mayo Clinic to advance development and product testing efforts.
NXgenPort s medical device helps providers like Mayo Clinic monitor cancer patients at home with an implantable chemo-port catheter (patent pending). NXgenPort combines proven chemo-port efficacy with sensor technology to measure and remotely monitor early onset of complications by reporting and tracking patient response over the course of their treatment. According to the Chief Science Officer at NXgenPort, Dr. Rosanne Welcher, NXgenPort will bring the benefits of remote patient monitoring to cancer patients, who may have limited support between their trea
Mayo Clinic is ramping up activity in the remote patient monitoring arena. Its latest move is a collaboration with biomedical technology company NXgenPort, which will focus on an implantable catheter that can remotely monitor cancer patients for complications as they undergo treatment.